CELC
Price
$15.36
Change
-$0.00 (-0.00%)
Updated
Nov 4 closing price
2 days until earnings call
SNDX
Price
$19.73
Change
+$0.79 (+4.17%)
Updated
Nov 5, 04:00 PM (EDT)
Earnings call today
Ad is loading...

CELC vs SNDX

Header iconCELC vs SNDX Comparison
Open Charts CELC vs SNDXBanner chart's image
Celcuity
Price$15.36
Change-$0.00 (-0.00%)
Volume$165.83K
CapitalizationN/A
Syndax Pharmaceuticals
Price$19.73
Change+$0.79 (+4.17%)
Volume$225.2K
CapitalizationN/A
View a ticker or compare two or three
CELC vs SNDX Comparison Chart
Loading...
CELC
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
SNDX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
CELC vs. SNDX commentary
Nov 06, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CELC is a Buy and SNDX is a Hold.

COMPARISON
Comparison
Nov 06, 2024
Stock price -- (CELC: $15.34 vs. SNDX: $18.94)
Brand notoriety: CELC and SNDX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CELC: 58% vs. SNDX: 141%
Market capitalization -- CELC: $563.97M vs. SNDX: $1.68B
CELC [@Biotechnology] is valued at $563.97M. SNDX’s [@Biotechnology] market capitalization is $1.68B. The market cap for tickers in the [@Biotechnology] industry ranges from $488.28B to $0. The average market capitalization across the [@Biotechnology] industry is $2.82B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CELC’s FA Score shows that 0 FA rating(s) are green whileSNDX’s FA Score has 1 green FA rating(s).

  • CELC’s FA Score: 0 green, 5 red.
  • SNDX’s FA Score: 1 green, 4 red.
According to our system of comparison, SNDX is a better buy in the long-term than CELC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CELC’s TA Score shows that 5 TA indicator(s) are bullish while SNDX’s TA Score has 3 bullish TA indicator(s).

  • CELC’s TA Score: 5 bullish, 4 bearish.
  • SNDX’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, CELC is a better buy in the short-term than SNDX.

Price Growth

CELC (@Biotechnology) experienced а -2.54% price change this week, while SNDX (@Biotechnology) price change was -1.41% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.79%. For the same industry, the average monthly price growth was +15.00%, and the average quarterly price growth was +10.61%.

Reported Earning Dates

CELC is expected to report earnings on Mar 20, 2025.

SNDX is expected to report earnings on Mar 05, 2025.

Industries' Descriptions

@Biotechnology (+4.79% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SNDX($1.61B) has a higher market cap than CELC($564M). CELC YTD gains are higher at: 5.285 vs. SNDX (-12.355). CELC has higher annual earnings (EBITDA): -76.03M vs. SNDX (-263.84M). SNDX has more cash in the bank: 432M vs. CELC (283M). SNDX has less debt than CELC: SNDX (1.13M) vs CELC (96.5M). SNDX has higher revenues than CELC: SNDX (3.5M) vs CELC (0).
CELCSNDXCELC / SNDX
Capitalization564M1.61B35%
EBITDA-76.03M-263.84M29%
Gain YTD5.285-12.355-43%
P/E RatioN/AN/A-
Revenue03.5M-
Total Cash283M432M66%
Total Debt96.5M1.13M8,540%
FUNDAMENTALS RATINGS
CELC vs SNDX: Fundamental Ratings
CELC
SNDX
OUTLOOK RATING
1..100
8257
VALUATION
overvalued / fair valued / undervalued
1..100
41
Fair valued
86
Overvalued
PROFIT vs RISK RATING
1..100
10043
SMR RATING
1..100
9797
PRICE GROWTH RATING
1..100
5659
P/E GROWTH RATING
1..100
1005
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CELC's Valuation (41) in the Miscellaneous Commercial Services industry is somewhat better than the same rating for SNDX (86) in the Biotechnology industry. This means that CELC’s stock grew somewhat faster than SNDX’s over the last 12 months.

SNDX's Profit vs Risk Rating (43) in the Biotechnology industry is somewhat better than the same rating for CELC (100) in the Miscellaneous Commercial Services industry. This means that SNDX’s stock grew somewhat faster than CELC’s over the last 12 months.

SNDX's SMR Rating (97) in the Biotechnology industry is in the same range as CELC (97) in the Miscellaneous Commercial Services industry. This means that SNDX’s stock grew similarly to CELC’s over the last 12 months.

CELC's Price Growth Rating (56) in the Miscellaneous Commercial Services industry is in the same range as SNDX (59) in the Biotechnology industry. This means that CELC’s stock grew similarly to SNDX’s over the last 12 months.

SNDX's P/E Growth Rating (5) in the Biotechnology industry is significantly better than the same rating for CELC (100) in the Miscellaneous Commercial Services industry. This means that SNDX’s stock grew significantly faster than CELC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CELCSNDX
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
81%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
83%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
77%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 8 days ago
83%
Bullish Trend 23 days ago
84%
Declines
ODDS (%)
Bearish Trend 5 days ago
88%
Bearish Trend 6 days ago
77%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
87%
N/A
Aroon
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
74%
View a ticker or compare two or three
Ad is loading...
CELC
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
SNDX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MACHX21.420.03
+0.14%
MoA Balanced Fund
YOVAX15.440.01
+0.06%
Yorktown Small-Cap A
IASRX22.18N/A
N/A
Delaware Ivy Asset Strategy Fund Cl R
FCIKX16.81-0.01
-0.06%
NYLI PineStone International Eq Inv Cl
MRFIX64.64-0.08
-0.12%
MFS Research I

CELC and

Correlation & Price change

A.I.dvisor indicates that over the last year, CELC has been loosely correlated with QSI. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if CELC jumps, then QSI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CELC
1D Price
Change %
CELC100%
+2.75%
QSI - CELC
42%
Loosely correlated
-1.35%
INZY - CELC
41%
Loosely correlated
+1.38%
PLRX - CELC
41%
Loosely correlated
-0.14%
SNDX - CELC
40%
Loosely correlated
-0.21%
ALLO - CELC
40%
Loosely correlated
+10.29%
More

SNDX and

Correlation & Price change

A.I.dvisor indicates that over the last year, SNDX has been loosely correlated with RCUS. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if SNDX jumps, then RCUS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SNDX
1D Price
Change %
SNDX100%
-0.21%
RCUS - SNDX
49%
Loosely correlated
+0.39%
FOLD - SNDX
46%
Loosely correlated
-1.13%
BEAM - SNDX
46%
Loosely correlated
+6.24%
RAPT - SNDX
45%
Loosely correlated
+2.24%
VCYT - SNDX
45%
Loosely correlated
+2.07%
More